Nomura Asset Management Co. Ltd. Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Nomura Asset Management Co. Ltd. decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,621 shares of the biotechnology company's stock after selling 1,016 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.06% of United Therapeutics worth $8,687,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth $1,636,000. Norges Bank acquired a new stake in United Therapeutics during the fourth quarter worth about $151,764,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in United Therapeutics by 11.4% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 32,246 shares of the biotechnology company's stock worth $11,490,000 after purchasing an additional 3,312 shares during the period. Korea Investment CORP boosted its holdings in United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares during the last quarter. Finally, Florida Financial Advisors LLC grew its stake in shares of United Therapeutics by 6.2% in the 4th quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock valued at $290,000 after buying an additional 48 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Remove Ads

United Therapeutics Stock Up 1.8 %

NASDAQ:UTHR traded up $5.38 on Wednesday, reaching $312.26. 461,017 shares of the company's stock were exchanged, compared to its average volume of 450,237. The firm has a market capitalization of $14.02 billion, a price-to-earnings ratio of 13.71, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 52-week low of $227.75 and a 52-week high of $417.82. The business has a fifty day moving average of $336.64 and a 200-day moving average of $355.09.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business posted $4.36 earnings per share. As a group, equities analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on UTHR shares. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $388.25.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $940,373.07. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,500 shares of company stock valued at $26,134,500. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.